Preethy Paul

CEO at ATB Antivirals Ltd

Presenter

Dr. Preethy Paul is CEO & Co-founder of ATB Antivirals Oy, a Finnish biotechnology company developing novel antiviral therapies that target viruses directly. She has over 15 years of experience in antiviral research, drug discovery, and translational development, with expertise spanning HPV biology, therapeutic development, and respiratory viral infections.

At ATB Antivirals, she leads the company’s strategy, fundraising, partnering, and advancement of its proprietary antiviral pipeline. The company’s lead program is a topical anti-HPV therapy being developed initially for genital warts, with potential expansion into cervical and other genital precancerous lesions. ATB is also developing a triple-action nasal spray for the prevention of respiratory viral infections, with potential relevance for seasonal outbreaks and future pandemics.

Her work bridges scientific innovation, biotechnology entrepreneurship, and commercialization, with a focus on advancing antiviral therapies toward clinical development and building global pharmaceutical and strategic partnerships.